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Abstract

Human papillomavirus (HPV) infection causes at least 650,000 anogenital and oropharyngeal cancers (OPC) worldwide annually.
A prophylactic vaccine against high-risk HPV types was approved in 2006 by the FDA, but still, the burden of HPV-related cancers
is constantly increasing. Thus, therapies that directly target HPV-antigens represent an attractive alternative therapeutic approach.
However, current research’ focus is on epitopes in E6 and E7 proteins despite a high expression of other HPV-related proteins in
tumors. Large efforts in targeting HPV antigens with cellular therapy or therapeutic vaccines has focused on E6 and E7 epitopes
presented by HLA-A*02:01 2. However, most patients with HPV16+ cancer do not express this allele, indicating a large unmet
clinical need in non-HLA-A*02:01 patients. In addition, although HLA-A*02:01 is common among Caucasians, only 9% and 12% of
people of Asian or African American decent, respectively, express it – demonstrating an inequality that should be corrected. Here,
we introduce a high-throughput and epitope-agnostic pipeline for HPV16-reactive T cell discovery and validation. The basis of the
pipeline is the functional expansion of antigen-specific T cells after stimulation with peptide-pulsed antigen-presenting cells, and
with it we can evaluate T cell responses against any epitope within each individual HPV16 protein. Our goal is to build a library of
TCRs that will meet the unmet need in terms of HLA-restriction and that targets any expressed HPV16 epitope.

Fig. 1: Pipeline for comprehensive TCR and cognate epitope discovery and validation
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Fig. 3: (A) Using GLPH2, TCR motifs were constructed, and a
HPV16-E6-TCR1 motif was found enriched in tumors vs PBMC in
patients with HPV16-positive HNSCC. (B) Association between
natural presence of the HPV16-E6-TCR1 motif and survival in
patients with HPV16-positive HNSCC.
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Fig. 2:HPV16-reactive T cell clones were identified in HPV16positive HNSCC patients (one patient shown here) using the
FEST assay that allows expansion of antigen-specific T cells.
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Fig. 4: Validation of target candidate on Jurkatluc TCR KO cells
transduced with HPV16-E6-TCR1 or HPV16-E1-TCR18
(negative ctr) using a dextramer staining.
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Fig. 5: (A) HPV16-TCR engaged 2 peptides (HPV16-E6.3 and
HPV16-E6.4) overlapping within 11mer. Signal measured by
luciferase assay using transduced Jurkatluc TCR KO cells. (B)
Concentration-dependent response of HPV16-E6-TCR1 to
compatible peptides (3,4) and non-compatible peptide (11)
determined by luciferase assay with Jurkatluc TCR KO cells
transduced with HPV16-E6-TCR1 and HLA-specific donor PBMC

